Provide Pre-approval Expanded Access of LY3437943

NCT07629401 · Available

Last updated 2026-07-13

This clinical trial provides early access to the experimental drug LY3437943 for patients with a serious or life-threatening condition before it is fully approved by regulatory agencies.

Status Available

Type Expanded access

What this study is testing ClinicalTrials.gov NCT07629401 ↗

Description as written by the study sponsor.

Provide pre-approval single patient expanded access of retatrutide for patients.

Treatments tested

Retatrutide also known as LY3437943 Drug

Sponsor	Eli Lilly and Company
Conditions studied	—
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07629401 ↗